Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Adana, Turkey.
J Ovarian Res. 2018 Mar 5;11(1):21. doi: 10.1186/s13048-018-0393-0.
The purpose of this retrospective study was to determine the prognosis of non-serous epithelial ovarian cancer (EOC) patients with exclusively retroperitoneal lymph node (LN) metastases, and to compare the prognosis of these women to that of patients who had abdominal peritoneal involvement.
A multicenter, retrospective department database review was performed to identify patients with stage III non-serous EOC at 7 gynecologic oncology centers in Turkey. Demographic, clinicopathological and survival data were collected. The patients were divided into three groups based on the initial sites of disease: 1) the retroperitoneal (RP) group included patients who had positive pelvic and /or para-aortic LNs only. 2) The intraperitoneal (IP) group included patients with > 2 cm IP dissemination outside of the pelvis. These patients all had a negative LN status, 3) The IP / RP group included patients with > 2 cm IP dissemination outside of the pelvis as well as positive LN status. Survival data were compared with regard to the groups.
We identified 179 women with stage III non-serous EOC who were treated at 7 participating centers during the study period. The median age of the patients was 53 years, and the median duration of follow-up was 39 months. There were 35 (19.6%) patients in the RP group, 72 (40.2%) in the IP group and 72 (40.2%) in the IP/RP group. The 5-year disease-free survival (DFS) rates for the RP, the IP, and IP/RP groups were 66.4%, 37.6%, and 25.5%, respectively (p = 0.002). The 5-year overall survival (OS) rate for the RP group was significantly longer when compared to those of the IP, and the IP/RP groups (74.4% vs. 54%, and 36%, respectively; p = 0.011). However, we were not able to define "RP only disease" as an independent prognostic factor for increased DFS or OS.
Primary non-serous EOC patients with node-positive-only disease seem to have better survival when compared to those with extra-pelvic peritoneal involvement.
本回顾性研究的目的是确定仅存在腹膜后淋巴结（LN）转移的非浆液性上皮性卵巢癌（EOC）患者的预后，并将这些女性的预后与有腹部腹膜受累的患者进行比较。
在土耳其的 7 个妇科肿瘤学中心进行了多中心回顾性部门数据库研究，以确定 III 期非浆液性 EOC 患者。收集人口统计学、临床病理学和生存数据。根据初始疾病部位将患者分为三组：1）腹膜后（RP）组包括仅盆腔和/或腹主动脉 LN 阳性的患者。2）腹腔内（IP）组包括骨盆外存在> 2cm IP 播散的患者。这些患者的 LN 状态均为阴性，3）IP/RP 组包括骨盆外存在> 2cm IP 播散且 LN 阳性的患者。比较各组的生存数据。
我们在研究期间确定了 179 名接受 7 个参与中心治疗的 III 期非浆液性 EOC 女性患者。患者的中位年龄为 53 岁，中位随访时间为 39 个月。RP 组有 35 例（19.6%），IP 组有 72 例（40.2%），IP/RP 组有 72 例（40.2%）。RP、IP 和 IP/RP 组的 5 年无病生存率（DFS）分别为 66.4%、37.6%和 25.5%（p=0.002）。与 IP 和 IP/RP 组相比，RP 组的 5 年总生存率（OS）明显更长（74.4%比 54%和 36%；p=0.011）。然而，我们无法将“仅 RP 疾病”定义为增加 DFS 或 OS 的独立预后因素。
与有盆腔外腹膜受累的患者相比，淋巴结阳性的非浆液性上皮性卵巢癌患者似乎具有更好的生存。
